Beneficial effect of cyproheptadine on body mass index in undernourished children: a randomized controlled trial

Khadijehsadat Najib, Mozhgan Moghtaderi, Zohreh Karamizadeh, Ebrahim Fallahzadeh, Khadijehsadat Najib, Mozhgan Moghtaderi, Zohreh Karamizadeh, Ebrahim Fallahzadeh

Abstract

Objective: Cyproheptadine hydrochloride (CH) is a first-generation antihistamine which is used as an appetite stimulant. This study was designed to identify the role of CH therapy on weight gain, linear growth and body mass index in children with mild to moderate undernutrition.

Methods: Eighty-nine patients were enrolled. The present randomized, double-blinded controlled trial included 77 evaluable patients, aged 24-64 months with undernutrition. The patients were randomized to receive cyproheptadine with multivitamin, or multivitamin over a period of four weeks. The weight, height and body mass index were measured at the baseline, four weeks after intervention and four weeks after discontinuation.

Findings: A significant higher body mass index was observed among CH-treated patients after 8 weeks intervention with cyproheptadine compared with the control group (P<0.041). Mean weight gain after eight weeks was 0.11 kg in the control group and 0.60 kg in the CH group. There were no significant differences in changes of weight and height velocity across the study between CH-treated and control group at the end of study.

Conclusion: In our study, cyproheptadine promotes increase in body mass index in children with mild to moderate undernutrition after four weeks treatment.

Keywords: Body Mass Index; Children; Clinical Trial; Cyproheptadine; Malnutrition; Weight Gain.

Figures

Fig. 1:
Fig. 1:
Trial profile
Fig. 2:
Fig. 2:
Weight, height and body mass index in cypro-treated and control groups before, 4 weeks after intervention and 1 month after discontinuation of cyproheptadine.

References

    1. Jeong SJM. Nutritional approach to failure to thrive. Korean J Pediatr 2011; 54 (7): 277– 81.
    1. Sharghi A, Kamran A, Faridan M. Evaluating risk factors for protein-energy malnutrition in children under the age of six years: a case-control study from Iran. Int J Gen Med 2011; 4: 607– 11.
    1. Sharifzadeh G, Mehrjoofard H, Raghebi S. Prevalence of malnutrition in under 6-year olds in South Khorasan, Iran. Iran J Pediatr 2010; 20 (4): 435– 41.
    1. Payandeh A, Saki A, Safarian M, et al. Prevalence of malnutrition among preschool children in northeast of Iran, a result of a population based study. Glob J Health Sci 2013; 5 (2): 208– 12.
    1. Bergman P, Graham J. An approach to failure to thrive. Aust Fam Physician 2005; 34 (9): 725– 9.
    1. Bergen SS., Jr Appetite Stimulating Properties of Cyproheptadine. Am J Dis Child 1964; 108: 270–3.
    1. Halmi KA, Goldberg SC. Cyproheptadine in anorexia nervosa. Psychopharmacol Bull 1978; 14 (2): 31– 3.
    1. Rerksuppaphol S, Rerksuppaphol L. Effect of cyproheptadine on weight gain in malnourished children: a randomized, controlled trial. Asian Biomed 2010; 4: 977– 82.
    1. Powers PS, Santana C. Available pharmacological treatments for anorexia nervosa. Expert Opin Pharmacother 2004; 5 (11): 2287– 92.
    1. Couluris M, Mayer JL, Freyer DR, et al. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. J Pediatr Hematol Oncol 2008; 3 0: 791– 7.
    1. Epifanio M, Marostica PC, Mattiello R, et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. J Pediatr (Rio J) 2012; 88 (2): 155– 60.
    1. Aguilera A, Selgas R, Diéz JJ, et al. Anorexia in end-stage renal disease: pathophysiology and treatment. Expert Opin Pharmacother 2001; 2 (11): 1825– 38.
    1. Dabaghzadeh F, Khalili H, Ghaeli P, et al. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz. Expert Opin Pharmacother 2012; 13 (18): 2613– 24.
    1. Gómez F, Ramos-Galvan R, Frenk S, et al. Mortality in second and third degree malnutrition. J Trop Pediatr (Lond) 1956; 2 (2): 77– 83.
    1. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009; 137 (1): 88– 93.
    1. Periactin® package insert. Whitehouse Station, NJ: Merck & Co; 2002.
    1. Crowley VE, Spiegelman BM. Obesity therapy: Altering the energy intake and expenditure balance sheet. Nat Rev Drug Disc 2002; 1 (4): 276– 81.
    1. Flier JS, Maratos-Flier E. Obesity. In: Kasper DL, et al. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005; pp 422–9.
    1. Herfindal ET, Gourley DR. Textbook of therapeutics drug and disease management. 7th ed. New York: Lippincott Williams and Wilkins; 2000; pp 1277–80.
    1. Ferriols LF, Tordera BM. Wasting syndrome in cancer patients: Pathophysiology, manifestations and drug therapy. Farm Hosp 2003; 27 (5): 308– 16.
    1. Mahachoklertwattana P, Wanasuwankul S, Poomthavorn P, et al. Short-term cyproheptadine therapy in underweight children: effects on growth and serum insulin-like growth factor-I. J Pediatr Endocrinol Metab 2009; 22 (5): 425– 32.
    1. Kaplowitz PB, Jennings S. Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. J Pediatr 1987; 110 (1): 140– 3.
    1. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol 2004; 14 (1): 65– 73.
    1. Nemati M, Habibi AsL B, Sharifi K. Effect of ketotifen and cyproheptadine on appetite and weight changes in mice. Iran J Pharmaceut Sci 2006; 2: 123– 8.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit